FDA approved durvalumab as maintenace for unresectable stage III NSCLC responding to platinum-based chemoradiation therapy

/0 Comments/in , /by

 

  • FDA approved durvalumab (Imfinzi, AstraZeneca Inc.) for patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. More Information.
You might also like
KEYNOTE-158-pembrolizumab-in-previously-treated-advanced-cervical-cancerFDA approved abiraterone acetate tablets plus prednisone for metastatic high-risk CSPC
Prof Stefan Kasper on I-O in EXTREME-ineligible SCCHN
KEYNOTE-158-pembrolizumab-in-previously-treated-advanced-cervical-cancerPembrolizumab FDA approved in hepatocellular carcinoma patients pretreated with sorafenib
KEYNOTE-158-pembrolizumab-in-previously-treated-advanced-cervical-cancerFDA approves apalutamide for non-metastatic castration-resistant prostate cancer
KEYNOTE-158-pembrolizumab-in-previously-treated-advanced-cervical-cancerBrigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC
KEYNOTE-158-pembrolizumab-in-previously-treated-advanced-cervical-cancerKEYNOTE-158: pembrolizumab in previously treated advanced cervical cancer
KEYNOTE-158-pembrolizumab-in-previously-treated-advanced-cervical-cancerPembrolizumab FDA approved for adjuvant treatment of melanoma
KEYNOTE-158-pembrolizumab-in-previously-treated-advanced-cervical-cancerLorlatinib FDA approved for metastatic ALK-positive NSCLC
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

FDA approves apalutamide for non-metastatic castration-resistant prostate c...FDA approved abemaciclib plus aromatase inhibitor for untreated postmenopausal...